UBS Group AG Acquires 104,546 Shares of ACADIA Pharmaceuticals Inc. $ACAD

UBS Group AG boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 15.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 769,392 shares of the biopharmaceutical company’s stock after buying an additional 104,546 shares during the period. UBS Group AG’s holdings in ACADIA Pharmaceuticals were worth $20,550,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ACAD. Royal Bank of Canada grew its position in shares of ACADIA Pharmaceuticals by 74.4% in the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock valued at $1,338,000 after buying an additional 34,352 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock worth $1,124,000 after acquiring an additional 2,492 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ACADIA Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock worth $1,498,000 after acquiring an additional 6,303 shares during the period. Empowered Funds LLC bought a new stake in ACADIA Pharmaceuticals in the first quarter valued at approximately $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in ACADIA Pharmaceuticals by 14.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock valued at $4,170,000 after acquiring an additional 31,931 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $21.80 on Tuesday. The stock has a market capitalization of $3.73 billion, a PE ratio of 9.91, a price-to-earnings-growth ratio of 25.16 and a beta of 0.86. ACADIA Pharmaceuticals Inc. has a 52 week low of $16.86 and a 52 week high of $28.35. The stock has a 50 day moving average price of $21.95 and a two-hundred day moving average price of $23.92.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The firm had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 9.7% on a year-over-year basis. Research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.42 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Citigroup lowered their price target on shares of ACADIA Pharmaceuticals from $33.00 to $32.00 and set a “buy” rating for the company in a report on Friday. Royal Bank Of Canada reduced their price objective on shares of ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Wolfe Research initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 1,332 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $29,024.28. Following the transaction, the insider directly owned 29,129 shares of the company’s stock, valued at approximately $634,720.91. This trade represents a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares of the company’s stock, valued at $1,441,299.55. This represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 8,577 shares of company stock worth $188,426. Corporate insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.